CG 메이저 바카라사이트 캡틴 projects performance rebound in 2025, driven by ‘genetic testing’ and ‘Acelex’

[by Ji, Yong Jun] CG Invites conveyed its confidence to shareholders regarding a performance turnaround expected within the year. Following the implementation of a co-CEO leadership structure led by Oh Soo-yeon and Lee Ho-young earlier this year, the company has strengthened its operational capabilities as a digital healthcare company, aiming to transition from a period of investment to one of tangible returns.

On June 21, CG 메이저 바카라사이트 캡틴 held a shareholder briefing at its Magok headquarters in Seoul, where it presented its outlook for performance improvement. Co-CEOs Oh Soo-yeon and Lee Ho-young, making their first public appearance since assuming their roles, reported on the company’s business progress and strategies to secure new growth engines. In Q1 2025, CG 메이저 바카라사이트 캡틴 recorded standalone sales of aboute KRW 1.8 billion (approximately USD 1.3 million) and an operating loss of about KRW 3.5 billion. Compared to the same period last year, sales increased by 260% from KRW 500 million, while the operating loss decreased by roughly 32%.

“Since assuming office, we have undertaken a comprehensive review and restructuring of the entire business,” stated Lee Ho-young, co-CEO of CG 메이저 바카라사이트 캡틴. “Our efforts thus far have been directed toward resolving accumulated challenges, and we are committed to achieving a performance turnaround within this year.”

At the end of March, CG 메이저 바카라사이트 캡틴 CEO Jung In-cheol, who had served as one of the co-CEOs, stepped down from his position, and Lee Ho-young was appointed as co-CEO alongside the incumbent Oh Soo-yeon. Lee, who has been with the group since 2013, has held leadership roles in various entities within the 메이저 바카라사이트 캡틴 Ecosystem, including serving as CEO of 메이저 바카라사이트 캡틴 Genomics. The 메이저 바카라사이트 캡틴 Ecosystem encompasses a network of healthcare companies structured to advance data-driven personalized health management, disease management, and AI-based disease prediction.

CG 메이저 바카라사이트 캡틴 identified the full-scale launch of its new genome testing service in April, along with the global market expansion of Acelex (polmacoxib), as key drivers of its anticipated performance turnaround.

“The genome 메이저 바카라사이트 캡틴 business, including prenatal screening, is demonstrating growth,” Oh stated. “It appears feasible to surpass the previous sales of KRW 2 billion.”

He further noted that the global market expansion of 메이저 바카라사이트 캡틴 is beginning to take shape. "Discussions regarding an order contract for 메이저 바카라사이트 캡틴 in Russia are currently in the final stages," Oh emphasized. "We are also preparing for market entry in Southeast Asia, with a focus on Brazil and Thailand."

CG 메이저 바카라사이트 캡틴 is establishing a foundation for sales growth centered on digital healthcare. Its parent company, 메이저 바카라사이트 캡틴 Ecosystem, announced that it will apply its core artificial intelligence (AI)-based healthcare technology platform, '메이저 바카라사이트 캡틴 Loop,' to urban infrastructure in Ulsan Metropolitan City's hub-type smart city development project.

‘메이저 바카라사이트 캡틴 Loop' is an AI-driven circular digital healthcare model that extends beyond basic health monitoring to encompass disease prediction → behavioral guidance → implementation → feedback. At the end of 2024, the company secured a contract for the 'Genome and Transcriptome Data Production and Basic Analysis component for the National Integrated Bio Big Data Construction Project,' currently underway by the government. The project is scheduled to run through December 2026, with a total contract value of KRW 5.6 billion.

CG 메이저 바카라사이트 캡틴 also provided an update on the civil lawsuit for damages amounting to approximately USD 100 million, filed last November by former founder Cho Joong-myung against its subsidiary CG Pharmaceuticals (CGP). “The legal proceedings are taking time to conclude, but we are responding proactively,” Oh stated. “Thus far, the circumstances appear to be favorable for the company.”